On September 9, 2025, Serina Therapeutics, Inc. entered into a $20 million unsecured convertible note with board member Gregory H. Bailey, with funds to be released in tranches tied to clinical milestones. The note features a 10% interest rate and is convertible into shares at $5.18 each.